|
US2021078956A1
|
|
Process for preparing elagolix sodium and intermediates thereof
|
|
US2020361951A1
|
|
Polymorphism for irinotecan free base
|
|
TW202102517A
|
|
Process for purifying liraglutide
|
|
US2020075128A1
|
|
Analyzing High Dimensional Data Based on Hypothesis Testing for Assessing the Similarity between Complex Organic Molecules Using Mass Spectrometry
|
|
US10703728B1
|
|
Crystalline form of olaparib and a process for preparing the same
|
|
US2019300512A1
|
|
Crystal forms of lifitegrast
|
|
WO2020013759A1
|
|
Method for preparing sugammadex sodium
|
|
TWI668236B
|
|
Method for preparing sugammadex sodium
|
|
US2018312612A1
|
|
Method for preparing sugammadex sodium
|
|
CA3068522A1
|
|
Process for preparing lifitegrast and intermediates thereof
|
|
US2018265472A1
|
|
Process for preparing aripiprazole lauroxil and intermediates thereof
|
|
US2019241606A1
|
|
Process for preparation of cangrelor tetrasodium and intermediate therefor
|
|
US2018208683A1
|
|
Method for preparing sugammadex sodium
|
|
TW201831461A
|
|
Process for preparing apalutamide
|
|
US10118937B1
|
|
Process for preparing ixazomib citrate and intermediates therefor
|
|
WO2018038680A1
|
|
Processes for preparing olaparib
|
|
TW201808922A
|
|
Process for preparing ataluren and its intermediates
|
|
US2017260186A1
|
|
Process of preparing amorphous form of idelalisib
|
|
US2017240520A1
|
|
Process for preparing SGLT2 inhibitors and intermediates thereof
|
|
US2017204067A1
|
|
Crystalline forms of olaparib and manufacturing processes therefor
|
